Angiotech announces license agreement between Surgical Specialties Corporation and Collagen Matrix Technologies Inc. for Dermal
29 März 2006 - 4:30PM
PR Newswire (US)
VANCOUVER, March 29 /PRNewswire-FirstCall/ -- Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP) today
announced the execution of a development, license and distribution
agreement between its wholly-owned subsidiary, Surgical Specialties
Corporation (SSC), and Collagen Matrix Technologies Inc. (CMT),
appointing SSC to be the exclusive worldwide distributor of CMT's
Dermalogen(TM) products for use in aesthetic surgery and
dermatology procedures. First introduced in 1998, Dermalogen(TM) is
an injectable, collagen-based dermal filler that can be used for
the correction of wrinkle lines and for the removal or improvement
of scars caused by trauma, surgery or acne. "We are excited to
complete our first business development initiative with our newly
acquired SSC product and sales franchise, and we feel
Dermalogen(TM) is a strong complement to our line of
aesthetic-based products," said Dr. William L. Hunter, President
and Chief Executive Officer of Angiotech. "We are looking forward
to working closely with CMT, and anticipate that this agreement
will further expand and develop our platform of products used for
aesthetic-based procedures. We believe that Dermalogen(TM) may also
have the advantage of being an alternative for patients who are
allergic to traditional collagen treatments," said Pete Molinaro,
President of Surgical Specialties Corporation. It is anticipated
that, pending completion of trials and obtaining regulatory
approval, SSC could be selling Dermalogen(TM) in the United States
within 18 months. About Dermalogen(TM) Dermalogen(TM) is an
injectable dermal filler that can be used for a variety of facial
cosmetic and reconstructive treatments. It addresses the facial
contour defects that cannot be treated effectively either with
laser-resurfacing or face lift surgery. These include glabellar
creases and depressed scars caused by trauma, surgery or acne. An
alternative to bovine collagen treatments, Dermalogen(TM) is
similar to native dermis and contains intact collagen fibrils,
elastic network, and proteoglycans to stimulate collagen production
and vascularization. About Angiotech Pharmaceuticals, Inc.
Angiotech Pharmaceuticals, Inc. is a global specialty
pharmaceutical company that discovers and develops innovative
treatment solutions for diseases or complications associated with
medical device implants, surgical interventions and acute injury or
trauma. To find out more about Angiotech Pharmaceuticals, Inc.
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at
http://www.angiotech.com/. About Surgical Specialties Corporation
Surgical Specialties Corporation is a wholly-owned subsidiary of
Angiotech Pharmaceuticals, which was acquired during the
acquisition of American Medical Instruments Holdings, Inc. in March
2006. Based in Reading, Pennsylvania, Surgical Specialties
Corporation is a specialty surgical device company engaged in wound
closure, aesthetic surgery and ophthalmology. It is best known for
the Sharpoint(TM) line of surgical needles and sutures,
Sharpoint(TM) ophthalmic microsurgical knives, and Contour
Threads(TM) barbed sutures for performing minimally invasive facial
ThreadLift(TM) Procedures. About Collagen Matrix Technologies Inc.
Based in Boca Raton, Florida, Collagen Matrix Technologies Inc. is
an innovative biomaterials company focused on developing and
manufacturing injectable collagen products for aesthetic
procedures, as well as plastic and reconstructive surgery. The
company owns a broad range of intellectual property to support its
collagen matrix technology platform. Forward-Looking Statements and
Historical Financial References This press release contains
forward-looking statements, which provide our current expectations
or forecasts of future events. In some cases, you can identify
forward-looking statements by words such as "anticipate," "believe"
or "intend," but the absence of those words does not necessarily
mean that a statement is not forward-looking. Forward-looking
statements are subject to known and unknown risks and uncertainties
and are based on potentially inaccurate assumptions that could
cause actual results to differ materially from those expected or
implied by the forward-looking statements. Our actual results could
differ materially from those anticipated in the forward-looking
statements for many reasons, including the factors described in the
section titled "Risks Related to Our Business" in our Management's
Discussion & Analysis of Financial Condition and Results of
Operations for the year ended December 31, 2005 and "Risk Factors"
in our annual information form for the year ended December 31, 2004
filed with the Securities and Exchange Commission. Other factors
besides those described in our MD&A and annual information form
could also affect actual results. You should carefully consider the
factors described in the sections referenced above when evaluating
our forward-looking statements. You should not unduly rely on these
forward-looking statements, which speak only as of the date of this
press release. We undertake no obligation to publicly update any
forward-looking statements to reflect circumstances or events after
the date of this press release, or to reflect the occurrence of
unanticipated events. You should, however, review the factors and
risks we describe in the reports we file from time to time with the
applicable Canadian securities commissions or similar regulatory
authorities or the Securities and Exchange Commission. For
Additional Information: Analysts and Investors: Rui Avelar, Chief
Medical Officer, Angiotech Pharmaceuticals, Inc. (604) 221-7676 ext
6933 Media: Colleen Beauregard, Waggener Edstrom Bioscience (503)
443-7863; Email: DATASOURCE: Angiotech Pharmaceuticals, Inc.
CONTACT: Analysts and Investors: Rui Avelar, Chief Medical Officer,
Angiotech Pharmaceuticals, Inc., (604) 221-7676 ext 6933; Media:
Colleen Beauregard, Waggener Edstrom Bioscience, (503) 443-7863,
Email:
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024